Proteomic modulation in breast tumors after metformin exposure: results from a “window of opportunity” trial

@article{Kalinsky2016ProteomicMI,
  title={Proteomic modulation in breast tumors after metformin exposure: results from a “window of opportunity” trial},
  author={Kevin Kalinsky and Tian Zheng and Hanina Hibshoosh and Xing Hua Du and Prabhjot S. Mundi and Jaeyoung Yang and Simone Refice and Sheldon Feldman and Bret Taback and E. Sander Connolly and Katherine D Crew and Matthew A. Maurer and Dawn L. Hershman},
  journal={Clinical and Translational Oncology},
  year={2016},
  volume={19},
  pages={180-188}
}
PurposeReverse Phase Protein Array (RPPA) is a high-throughput antibody-based technique to assess cellular protein activity. The goal of this study was to assess protein marker changes by RPPA in tumor tissue from a pre-surgical metformin trial in women with operable breast cancer (BC).MethodsIn an open-label trial, metformin 1500-mg PO daily was administered prior to resection in 35 non-diabetic patients with stage 0–III BC, body mass index ≥25 kg/m2. For RPPA, formalin-fixed paraffin-embedded… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 46 REFERENCES

Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2013
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Effects of metformin on retinoblastoma growth in vitro and in vivo

K Brodowska, S Theodoropoulou, +3 authors G Scott
  • Int J Oncol
  • 2014
VIEW 1 EXCERPT

Influence of biospecimen variables on proteomic biomarkers in breast cancer.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2014
VIEW 2 EXCERPTS